Focus Partners Wealth
CGTX icon

Focus Partners Wealth’s Cognition Therapeutics CGTX Stock Holding History

Focus Partners Wealth’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4K Hold
15,000
– – ﹤0.01% 2630
2025
Q4 		$20.3K Hold
15,000
– – ﹤0.01% 2627
2025
Q3 		$20.3K Buy
+15,000
New +$20.5K ﹤0.01% 2185

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Focus Partners Wealth's CGTX Position: Q1 2026 in Review

Focus Partners Wealth held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 15,000 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Focus Partners Wealth first reported a position in CGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $20.3K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Focus Partners Wealth held 15,000 shares of Cognition Therapeutics worth $11.4K as of Q1 2026.
  • Focus Partners Wealth left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2630 holding.
  • Focus Partners Wealth first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Focus Partners Wealth's Cognition Therapeutics position peaked at $20.3K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.